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Subclinical Interstitial Lung Abnormalities: Lumping and
Splitting Revisited
Identifying patients with idiopathic pulmonary fibrosis (IPF) at
the earliest opportunity remains one of the most urgent challenges
for the effective management of this deadly disease. A theoretical
basis for early IPF detection comes from large lung cancer and
cardiovascular cohort studies that have reported shared clinical
associations between incidentally detected subclinical interstitial
lung abnormalities (ILAs) on computed tomography (CT) and IPF
(1). ILAs are more prevalent with increasing age (2–4), in smokers
(1, 5, 6), and in patients over the age of 50 who exhibit MUC5B
promoter polymorphism positivity (4). ILAs are also associated
with a reduction in pulmonary function (1, 5) and exercise capacity
(7). Importantly, patients with progressive ILAs demonstrate
greater serial pulmonary function decline when compared with
patients with stable ILAs (8). However, the consistent observation
that ILA prevalence exceeds that of IPF by more than an order of
magnitude means that refinement of current ILA definitions and
identification of progressive ILA subtypes are critical if screening
for early IPF is to be successful (1).
In this issue of the Journal, Putman and colleagues (pp. 175–
183) extend their impressive portfolio of ILA studies by evaluating
the impact of specific ILA features on ILA progression as judged
by follow-up CT in a population of adults from the AGES-
Reykjavik (Age, Gene/Environment Susceptibility–Reykjavik)
study (9). This study is important because it represents the first
attempt to identify specific CT features and radiologic patterns
linked to the progressive ILA phenotype. ILAs defined as
subpleural and reticular, those associated with traction
bronchiectasis, and ILAs with a lower-lobe predilection were
associated with a greater than sixfold likelihood of progression.
Moreover, in 16 patients with ILAs characterized by
honeycombing, all five who had follow-up imaging had
progressed. The authors also generated a “definite fibrosis” score
by amalgamating traction bronchiectasis and honeycombing,
which was associated with a greater than eightfold likelihood of
progression. Finally, previously reported clinical associations with
ILA progression, including increasing age and MUC5B promoter
polymorphism positivity, were confirmed.
The importance of standardizing ILA definitions cannot be
overstated, and the authors make a considerable effort to maintain
consistency and clarity in this regard. However, two issues warrant
consideration. First, the separation of fibrotic from nonfibrotic ILA
is crucial but challenging in limited or early disease because CT-
histologic correlation in this setting is imperfect. In one patient,
limited subpleural reticulation may be the sole CT manifestation of
advanced fibrosis histologically, but in another patient it may not
represent fibrosis at all (10). The authors attempt to address this
issue by combining traction bronchiectasis and honeycombing, two
reliable CT signs of fibrosis, as one variable (“definite fibrosis”), but
this is likely to miss at least some cases of reticular ILA
representing real fibrotic disease. It is interesting to note that the
latest iteration of the international evidence-based joint clinical
practice guideline for IPF diagnosis includes in its definition of
“indeterminate” for usual interstitial pneumonia (UIP) on CT
“subtle reticulation,” which is also described as an “early UIP”
pattern (11). In the study by Putman and colleagues, the prevalence
of reticular ILA is more than 80%, but only 34% of these cases were
considered to represent “definite fibrosis” (9).
The second, related issue is that if “definite fibrosis” is confined
to ILAs in which traction bronchiectasis or honeycombing is present,
what defines the boundary between this subtype of fibrotic ILA and
the presence of established fibrotic lung disease? In the study by
Putman and colleagues, patients whose pattern of ILA met guideline
criteria for “probable” or “definite” UIP were included in the analysis
and, as expected, all of these patients progressed. Furthermore,
89%/100% of those with a “probable”/“definite” UIP pattern,
respectively, died at the end of the follow-up period. The inclusion of
these patients raises questions regarding the overarching definition of
ILA: “imaging abnormalities on chest CT in research participants
without a clinical diagnosis of interstitial lung disease.” Based on
current guidelines, the majority of these patients would meet
diagnostic criteria for IPF (11). Although there is currently no
evidence showing that a UIP pattern on chest CT predicts outcome
in research participants who have not received a diagnosis, our
understanding of UIP as the prototypic progressive radiologic
phenotype is supported by a large body of evidence across idiopathic
and nonidiopathic fibrotic lung disease cohorts (12–15). If a
screening strategy for detecting early IPF is to be successful, we
should probably focus our efforts on determining which of the ILAs
that are currently considered nonspecific represent early and
clinically relevant progressive fibrotic lung disease (Figure 1).
Undoubtedly, a set of standard definitions that would allow
consistent ILA reporting and harmonization of cohorts to power
larger studies is urgently required. How these definitions should be
devised is less clear. Taxonomy can be a double-edged sword that,
when wielded indiscriminately, merely replaces understanding with
filing—the crux of the well-known “lumping and splitting” debate.
Categories that are too rigorously defined lead to distinctions without
a difference or impracticable precision, particularly when knowledge
is incomplete. Overlapping ILA patterns may exist that by definition
cannot be easily placed within a single category. ILA distribution in
three dimensions is also likely to be significant based on our
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knowledge of ILD, but it can be notoriously difficult to classify
visually. Finally, pattern recognition on CT is liable to substantial
interobserver variability even among experts (16, 17). Thoracic
radiologists have difficulties agreeing on a radiologic diagnosis when
an established fibrotic lung disease is present; how agreement on ILA
definitions will be impacted when the abnormalities are sparse or
poorly defined is anyone’s guess. In the current study, the authors
report a concordance rate of 81% for the categorization of ILA as
present, indeterminate, or absent, but the concordance regarding the
classification of ILA subtypes is not clear.
These issues raise tantalizing possibilities for the application of
computational image analysis to ILA classification. Over the past
decade, there has been a surge in quantitative CT (QCT) research
in the ILD setting. Quantitative CT can detect subtle disease
progression and prognostic imaging features that elude human
assessment (18, 19). These benefits, combined with computer
objectivity, are making imaging biomarker exploration in
fibrotic lung disease based on visual scoring outdated. More
advanced machine-learning methods, and in particular deep
learning–based image analysis, will undoubtedly enable further
progress in this field, particularly in the domain of new knowledge
generation (20, 21). Deep learning is particularly suited to
discovering intricate patterns in high-dimensional data, such as
images, and mapping them to simple but objective classifications,
such as disease progression and mortality. When applied to an
appropriately sized cohort, this technology has the potential to
facilitate the discovery of radiologic phenotypes representing
subclinical fibrotic lung disease that encompass pattern,
distribution, and any other predictive CT parameter, including
ones imperceptible to human observers. These radiologic
phenotypes could be combined with digital lung sound signatures
or serum biomarkers to further improve detection of subclinical
fibrotic lung disease (22, 23). In the context of the unmet
clinical need represented by subclinical IPF detection, the
application of computer-based image analysis is undoubtedly a
compelling next step. n
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Figure 1. Progressive fibrotic interstitial lung abnormalities (ILAs) represent a subtype of ILAs that progress to symptomatic progressive fibrotic interstitial
lung disease (PF-ILD), of which idiopathic pulmonary fibrosis (IPF) is one form. The challenge is to determine with accuracy which forms of ILA belong to
the progressive fibrotic ILA subtype.
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A Long Noncoding RNA links TGF-b Signaling in Lung Fibrosis
Pulmonary fibrosis is an increasing cause of morbidity and
mortality worldwide with limited therapeutic options. Idiopathic
pulmonary fibrosis (IPF) is a particularly severe form of lung
fibrosis, with no known etiology and a median survival of 2.5–3.5
years after diagnosis (1). The pathogenesis of IPF is complex
and involves loss of epithelial integrity and excessive fibroblast
activation (1, 2).
The TGF-b (transforming growth factor b) signaling pathway
plays a central role in the initiation and progression of tissue
fibrosis (3). Strategies to target the TGF-b signaling pathway have
been extensively investigated in preclinical settings (4) and in
clinical trials for patients with IPF. Owing to the pleiotropic nature
of TGF-b, directly blocking TGF-b signaling may have adverse
effects. Alternative strategies, such as partial inhibition of TGF-b
using avb6 integrin antibodies, have been investigated (5).
In addition to protein-coding RNAs, many noncoding
RNAs (ncRNAs), including microRNAs (miRNAs) and long
ncRNAs (lncRNAs), have been recently described. miRNAs
are short (z22 nt in length), single-stranded ncRNAs that
inhibit the production of target proteins or induce the
degradation of mRNAs, thereby suppressing target gene
expression. Dysregulation of miRNAs has been shown in the
lungs of patients with IPF (6), as well as in animal models of lung
fibrosis (7). The roles of miRNAs in lung fibrosis have been studied
in humans and in mice (8, 9). lncRNAs are RNA transcripts that are
more than 200 nt long and may play a role in gene transcriptional
regulation, post-transcriptional regulation, and epigenetic regulation
in development and diseases (10).
In this issue of the Journal, Savary and colleagues (pp. 184–
198) report that the lncRNA DNM3OS (DNM3 opposite
strand/antisense RNA) serves as an miRNA reservoir in TGF-b
signaling (11). Using RNA sequencing and small RNA sequencing
in a human lung fibroblast cell line (MRC-5) stimulated with TGF-
b1, the authors found that the lncRNA DNM3OS was one of the
most strongly induced lncRNAs. Fluorescent in situ hybridization
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